Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Eric Wu

TitleAffiliate - DHHA
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-EM MED Clinical

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Garrison LP, Pezalla E, Towse A, Yang H, Faust E, Wu EQ, Li N, Sawyer EK, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value Health. 2021 Nov; 24(11):1628-1633. PMID: 34711363.
      View in: PubMed
    2. Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv. 2021 04 13; 5(7):1954-1962. PMID: 33830206.
      View in: PubMed
    3. Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Wu EQ, Kwong WJ, Abraham JA. The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States. J Occup Environ Med. 2021 04 01; 63(4):e197-e202. PMID: 33560066.
      View in: PubMed
    4. Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. Transplant Cell Ther. 2021 06; 27(6):506.e1-506.e10. PMID: 33823168.
      View in: PubMed
    5. Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. J Med Econ. 2021 Jan-Dec; 24(1):234-243. PMID: 33472483.
      View in: PubMed
    6. Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. Transplant Cell Ther. 2021 03; 27(3):241.e1-241.e11. PMID: 33781519.
      View in: PubMed
    7. Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020 08; 36(8):1333-1341. PMID: 32459116.
      View in: PubMed
    8. Yang H, Hao Y, Qi CZ, Chai X, Wu EQ. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective. J Manag Care Spec Pharm. 2020 Aug; 26(8):971-980. PMID: 32525730.
      View in: PubMed
    9. Yang H, Hao Y, Chai X, Qi CZ, Wu EQ. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective. J Med Econ. 2020 Sep; 23(9):1016-1024. PMID: 32397772.
      View in: PubMed
    10. Liu G, Wu EQ, Ahn J, Kamae I, Xie J, Yang H. The Development of Health Technology Assessment in Asia: Current Status and Future Trends. Value Health Reg Issues. 2020 May; 21:39-44. PMID: 31634795.
      View in: PubMed
    11. Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ. The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis. J Manag Care Spec Pharm. 2019 Dec; 25(12):1398-1408. PMID: 31566054.
      View in: PubMed
    12. Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R. Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis. Diabetes Ther. 2018 Jun; 9(3):1021-1036. PMID: 29600504.
      View in: PubMed
    13. Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018 06; 34(6):971-978. PMID: 29368958.
      View in: PubMed
    14. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The Cost of Hyperkalemia in the United States. Kidney Int Rep. 2018 Mar; 3(2):385-393. PMID: 29725642.
      View in: PubMed
    15. Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2017 Sep; 26(9):1996-2003. PMID: 28689999.
      View in: PubMed
    16. Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. J Manag Care Spec Pharm. 2017 Jul; 23(7):771-780. PMID: 28650249.
      View in: PubMed
    17. Soliman AM, Du EX, Yang H, Wu EQ, Haley JC. Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy. J Womens Health (Larchmt). 2017 06; 26(6):644-654. PMID: 28472602.
      View in: PubMed
    18. Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ. A Risk Score for Fluconazole Failure among Patients with Candidemia. Antimicrob Agents Chemother. 2017 05; 61(5). PMID: 28264843.
      View in: PubMed
    19. Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ. Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests. J Med Econ. 2017 Aug; 20(8):777-785. PMID: 28406042.
      View in: PubMed
    20. Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R. Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther. 2017 Jun; 8(3):555-571. PMID: 28361464.
      View in: PubMed
    21. Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Adv Ther. 2017 01; 34(1):207-220. PMID: 27913989.
      View in: PubMed
    22. Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017 Feb; 20(2):121-128. PMID: 27570999.
      View in: PubMed
    23. Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. J Blood Med. 2016; 7:129-37. PMID: 27445511.
      View in: PubMed
    24. Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guérin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97. PMID: 27216253.
      View in: PubMed
    25. Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J. Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. Antimicrob Agents Chemother. 2016 06; 60(6):3398-406. PMID: 27001815.
      View in: PubMed
    26. Guérin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother. 2016 Jun; 17(9):1189-96. PMID: 27052735.
      View in: PubMed
    27. Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis. Clin Ther. 2016 05; 38(5):1205-16. PMID: 27045991.
      View in: PubMed
    28. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites. Clin Ther. 2016 04; 38(4):905-17. PMID: 26947172.
      View in: PubMed
    29. Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guérin A. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Curr Med Res Opin. 2016; 32(2):385-94. PMID: 26651842.
      View in: PubMed
    30. Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guérin A. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. J Med Econ. 2016; 19(4):414-23. PMID: 27032967.
      View in: PubMed
    31. Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Dec 29; 15:167. PMID: 26714746.
      View in: PubMed
    32. Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey. Cancer Med. 2016 Feb; 5(2):209-20. PMID: 26686532.
      View in: PubMed
    33. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol. 2015; 4:31. PMID: 26693096.
      View in: PubMed
    34. Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respir Med. 2015 Dec; 109(12):1582-8. PMID: 26607877.
      View in: PubMed
    35. Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. Expert Opin Pharmacother. 2015; 16(14):2101-11. PMID: 26290278.
      View in: PubMed
    36. Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin. 2015 Aug; 31(8):1573-82. PMID: 26074049.
      View in: PubMed
    37. Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer. J Comp Eff Res. 2015 Aug; 4(4):315-26. PMID: 26274793.
      View in: PubMed
    38. Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. Clin Ther. 2015 Aug; 37(8):1713-25.e3. PMID: 26111918.
      View in: PubMed
    39. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. Int J Breast Cancer. 2015; 2015:240750. PMID: 26078883.
      View in: PubMed
    40. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin. 2015 Jun; 31(6):1095-103. PMID: 25971725.
      View in: PubMed
    41. Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ. Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. J Manag Care Spec Pharm. 2015 Apr; 21(4):308-18. PMID: 25803764.
      View in: PubMed
    42. Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health. 2015 Mar; 18(2):198-205. PMID: 25773555.
      View in: PubMed
    43. Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Curr Med Res Opin. 2015 Mar; 31(3):537-45. PMID: 25598441.
      View in: PubMed
    44. Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. Fertil Steril. 2015 Jan; 103(1):163-71. PMID: 25455535.
      View in: PubMed
    45. Mody R, Guérin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Prevalence and risk of developing comorbid conditions in patients with chronic constipation. Curr Med Res Opin. 2014 Dec; 30(12):2505-13. PMID: 25215427.
      View in: PubMed
    46. Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China. Pharmacoeconomics. 2014 Mar; 32(3):305-13. PMID: 24500859.
      View in: PubMed
    47. Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. Appl Health Econ Health Policy. 2014 Feb; 12(1):85-93. PMID: 24385260.
      View in: PubMed
    48. Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2013; 16(2):260-2. PMID: 23176287.
      View in: PubMed
    49. Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ. 2013; 16(2):278-88. PMID: 23153318.
      View in: PubMed
    50. Wu EQ, Forsythe A, Guérin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012 Nov; 19(6):e157-66. PMID: 21317625.
      View in: PubMed
    51. Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012 Sep-Oct; 15(6):940-7. PMID: 22999145.
      View in: PubMed
    52. Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012 Jul; 29(7):620-34. PMID: 22843208.
      View in: PubMed
    53. Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ. 2012; 15(6):1078-87. PMID: 22537226.
      View in: PubMed
    54. Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. J Med Econ. 2012; 15(4):786-95. PMID: 22475042.
      View in: PubMed
    55. Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012 Jan; 124(1):124-32. PMID: 22314122.
      View in: PubMed
    56. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011 Dec; 105(12):1861-71. PMID: 21807487.
      View in: PubMed
    57. Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ. 2011; 14(5):542-52. PMID: 21728912.
      View in: PubMed
    58. Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):326-35. PMID: 21700528.
      View in: PubMed
    59. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011; 14(3):315-23. PMID: 21500975.
      View in: PubMed
    60. Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP. Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ. 2011; 14(3):267-78. PMID: 21446895.
      View in: PubMed
    61. Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother. 2011 Apr; 45(4):441-51. PMID: 21415162.
      View in: PubMed
    62. Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011 Feb 01; 12(1):51-62. PMID: 21110526.
      View in: PubMed
    63. Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. Am J Cardiovasc Drugs. 2011; 11(1):21-32. PMID: 21142294.
      View in: PubMed
    64. Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M. Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. J Med Econ. 2010; 13(4):599-609. PMID: 20879834.
      View in: PubMed
    65. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010 Sep; 26(9):2065-76. PMID: 20629600.
      View in: PubMed
    66. Loftus EV, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2009 Nov; 21(11):1302-9. PMID: 19465858.
      View in: PubMed
    67. Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ. 2009 Jun; 12(2):124-35. PMID: 19566483.
      View in: PubMed
    68. Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009 May; 36(5):1032-40. PMID: 19369467.
      View in: PubMed
    69. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. PMID: 19352339.
      View in: PubMed
    70. Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008 Dec; 24(12):3493-501. PMID: 19032131.
      View in: PubMed
    71. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41. PMID: 18853973.
      View in: PubMed
    72. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. PMID: 18848553.
      View in: PubMed
    73. Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation. 2008 Jul 29; 118(5):491-7. PMID: 18625894.
      View in: PubMed
    74. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health. 2007 Nov-Dec; 10(6):443-50. PMID: 17970926.
      View in: PubMed
    75. Wu EQ, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health. 2007 Sep-Oct; 10(5):408-14. PMID: 17888106.
      View in: PubMed
    76. Colice G, Wu EQ, Birnbaum H, Daher M, Maryna M. Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma. 2007 Jul-Aug; 44(6):479-83. PMID: 17654136.
      View in: PubMed
    77. Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring). 2007 Feb; 15(2):511-21. PMID: 17299125.
      View in: PubMed
    78. Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006 Oct; 37(10):2567-72. PMID: 16946158.
      View in: PubMed
    79. Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006 Nov; 36(11):1535-40. PMID: 16907994.
      View in: PubMed
    80. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006 Aug; 48(8):794-802. PMID: 16902372.
      View in: PubMed
    81. Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H. Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population. Pharmacoeconomics. 2006; 24(1):55-65. PMID: 16445303.
      View in: PubMed
    82. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005 Sep; 66(9):1122-9. PMID: 16187769.
      View in: PubMed
    83. Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005 Oct 15; 58(8):668-76. PMID: 16023620.
      View in: PubMed
    84. Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005 May; 47(5):439-46. PMID: 15891521.
      View in: PubMed
    Wu's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)